Anemia in Chronic Kidney Disease

Fang, Yi; He, Weichun

doi:10.1007/978-981-32-9131-7_10

Cited by 2 publications

(2 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Global Burden of Disease in 2010 stated that CKD was the 18 th leading cause of death. A serious increase in mortality and morbidity occurs when progressing towards end-stage renal disease (ESRD) (Hill et al, 2016;Kemenkes RI & Pusat Data dan Informasi Kemenkes RI, 2017;Wheeler & Winkelmayer, 2017;Yang & He, 2019;Zhang et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Plasma Galectin-3 Biomarkers in Chronic Kidney Disease

Fadella

Harun

Priyono

et al. 2023

IJOMS

View full text Add to dashboard Cite

Assessment of renal function is based on determination of serum creatinine and creatinine-based equations to assess GFR. However, this marker is not perfect or accurate, especially for longitudinal monitoring of kidney function in Chronic Kidney Disease (CKD patients). Decreased kidney function can be slowed or even anticipated with early detection, so as to avoid secondary complications. So it is important to find new biomarkers that can identify individuals at risk as early as possible. Plasma galectin-3 is a ?-galactoside-binding lectin expressed in monocytes, which plays an important role in inflammation, immunity, cancer, and is involved in the pathogenesis of atherosclerosis, diabetes, renal fibrosis and asthma. Higher galectin-3 levels were associated with reduced eGFR in a cross-sectional study. Galectin-3 is essential in various biological activities including cell growth, cell proliferation, differentiation, apoptosis, pre-mRNA splicing, transformation, angiogenesis, inflammation, fibrosis, fibrogenesis and host defense. Galectin-3 is a stable biomarker and is not associated with age, body mass index or sex. Galectin-3 is also useful for detecting the early stages of some diseases. Galectin-3 shows no circadian variation and increases slightly after exercise, returning to normal levels after 1-3 hours. Higher concentrations of galectin-3 may be associated with CKD development, indicating the potential for new mechanisms related to galectin-3 expression that may contribute to CKD development. Galectin-3 has also been reported to play an important role in renal interstitial fibrosis. Thus, galectin-3 inhibition may be a promising therapeutic strategy to prevent kidney disease progression.

show abstract

Section: Introductionmentioning

confidence: 99%

Plasma Galectin-3 Biomarkers in Chronic Kidney Disease

Fadella

Harun

Priyono

et al. 2023

IJOMS

View full text Add to dashboard Cite

show abstract

“…[ 10 11 ] On the other hand, a low level of serum zinc could intensify hemolysis during HD process and its mechanical damage. [ 12 ]…”

Section: Introductionmentioning

confidence: 99%

The effect of oral zinc on hemoglobin and dose of erythropoietin in hemodialysis patients

Seirafian,

Feizi,

Shahidi

et al. 2023

Journal of Research in Medical Sciences

View full text Add to dashboard Cite

Background: In hemodialysis (HD) patients, low serum zinc level could cause hyporesponsivity to erythropoiesis-stimulating agents and lead to anemia. This study investigated the effects of oral zinc supplements on the required dose of erythropoietin in patients undergoing HD. Materials and Methods: In a double-blinded randomized trial, 76 HD patients were assigned to 2 groups of 38. One group (intervention) was treated with oral zinc supplements of 210 mg, daily for 6 months, and the other group (control) used placebo capsules for 6 months. The serum zinc level, hemoglobin level, and required dose of erythropoietin, albumin, ferritin, ferrous, and total iron-binding capacity were evaluated 3 and 6 months after intervention. Results: Repeated measures ANOVA did not show a significant increase in Hb level after 6 months of intervention (P = 0.28). However, the required dose of erythropoietin was decreased, but the changes were not statistically significant (P > 0.05). The changes in the other variables were not statistically significant. Conclusion: Oral zinc supplementation in HD patients could not increase hemoglobin level irrespective of their serum zinc level.

show abstract

Anemia in Chronic Kidney Disease

Cited by 2 publications

References 67 publications

Plasma Galectin-3 Biomarkers in Chronic Kidney Disease

Plasma Galectin-3 Biomarkers in Chronic Kidney Disease

The effect of oral zinc on hemoglobin and dose of erythropoietin in hemodialysis patients

Contact Info

Product

Resources

About